Novartis | NOVN - Passivo Circulante





Passivo Circulante Alterar Data
AbbVie USD 41.64B 458M 2026-06
Alcon AG USD 3.17B 163M 2026-06
Almirall EUR 323.65M 26.99M 2026-06
Amgen USD 25.5B 547M 2026-06
AstraZeneca USD 31.55B 1.02B 2026-06
Autolus Therapeutics Ltd USD 68.79M 5.19M 2026-06
Bayer EUR 32.27B 1.19B 2026-06
Biogen USD 3.92B 918.2M 2026-06
Bristol-Myers Squibb USD 18.66B 499M 2026-06
Eli Lilly USD 47.74B 11.11B 2026-06
Fresenius EUR 9.07B 468M 2026-06
Fresenius Medical Care EUR 7.18B 448.03M 2026-06
Genmab DKK 1.14B 38M 2026-06
Gilead Sciences USD 11.02B 1.54B 2026-06
GlaxoSmithKline GBP 21.53B 895M 2026-06
GRIFOLS EUR 2.24B 112M 2026-06
Hikma Pharmaceutical USD 1.45B 603M 2025-12
J&J USD 54.9B 2.82B 2026-06
Lakefront Biotherapeutics EUR 70.32M 30.1M 2026-06
Lonza CHF 3.57B 421M 2025-12
Merck EUR 8.12B 1.22B 2026-06
Merck USD 27.73B 786M 2026-06
Novartis USD 31.75B 374M 2026-06
Novartis USD 31.37B 4.1B 2026-03
Novo Nordisk DKK 239.08B 13.92B 2026-06
Orion EUR 454.5M 344.1M 2026-06
Pfizer USD 32.65B 1.7B 2026-06
Philips EUR 7.42B 8M 2026-06
Recordati EUR 1.4B 30.88M 2026-06
Regeneron Pharmaceuticals USD 5.53B 422.9M 2026-06
Roche Holding CHF 28.85B 846M 2026-06
Sanofi EUR 31.93B 1.92B 2026-06
UCB EUR 4.4B 470M 2025-12